A5021719278- Neuroendocrine Tumor Research Advances
- Lung Cancer Research Studies
- Neuroblastoma Research and Treatments
- Pancreatic and Hepatic Oncology Research
- Gestational Trophoblastic Disease Studies
- Gastrointestinal Tumor Research and Treatment
- Pituitary Gland Disorders and Treatments
- PI3K/AKT/mTOR signaling in cancer
- Gyrotron and Vacuum Electronics Research
- Cancer Treatment and Pharmacology
- Radiopharmaceutical Chemistry and Applications
- Lung Cancer Treatments and Mutations
- Adrenal and Paraganglionic Tumors
- Parathyroid Disorders and Treatments
- Medical Imaging Techniques and Applications
- Crustacean biology and ecology
- Metastasis and carcinoma case studies
- Thyroid Disorders and Treatments
- Chemotherapy-induced cardiotoxicity and mitigation
- Gastrointestinal disorders and treatments
- Gastric Cancer Management and Outcomes
- Intramuscular injections and effects
- Multiple and Secondary Primary Cancers
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Adenosine and Purinergic Signaling
Mount Sinai Hospital
2025
Icahn School of Medicine at Mount Sinai
2018-2025
Dana-Farber Cancer Institute
2017-2024
Mayo Clinic
2024
Boston Medical Center
2024
Tisch Cancer Institute
2021
University of Kentucky
2014-2019
Montefiore Medical Center
2016-2019
Albert Einstein College of Medicine
2016-2019
Cedars-Sinai Medical Center
2008-2019
Everolimus, an oral inhibitor of mammalian target rapamycin (mTOR), has shown antitumor activity in patients with advanced pancreatic neuroendocrine tumors, two phase 2 studies. We evaluated the agent a prospective, randomized, 3 study.
Patients with advanced midgut neuroendocrine tumors who have had disease progression during first-line somatostatin analogue therapy limited therapeutic options. This randomized, controlled trial evaluated the efficacy and safety of lutetium-177 (177Lu)–Dotatate in patients advanced, progressive, somatostatin-receptor–positive tumors.
Somatostatin analogues are commonly used to treat symptoms associated with hormone hypersecretion in neuroendocrine tumors; however, data on their antitumor effects limited.We conducted a randomized, double-blind, placebo-controlled, multinational study of the somatostatin analogue lanreotide patients advanced, well-differentiated or moderately differentiated, nonfunctioning, receptor-positive tumors grade 1 2 (a tumor proliferation index [on staining for Ki-67 antigen] <10%) and documented...
Purpose Neuroendocrine tumor (NET) progression is associated with deterioration in quality of life (QoL). We assessed the impact 177Lu-Dotatate treatment on time to health-related QoL. Methods The NETTER-1 trial an international phase III study patients midgut NETs. Patients were randomly assigned versus high-dose octreotide. European Organisation for Research and Treatment Cancer quality-of-life questionnaires QLQ C-30 G.I.NET-21 during determine completed at baseline every 12 weeks until...
In the CLARINET study, lanreotide Autogel (depot in USA) significantly prolonged progression-free survival (PFS) patients with metastatic pancreatic/intestinal neuroendocrine tumours (NETs). We report long-term safety and additional efficacy data from open-label extension (OLE). Patients grade 1/2 (Ki-67 ≤10%) non-functioning NET documented baseline tumour-progression status received 120 mg ( n =101) or placebo =103) for 96 weeks until death/progressive disease (PD) study. stable (SD) at...
Abstract: In a randomized, double-blind, Phase III study, we compared pasireotide long-acting release (pasireotide LAR) with octreotide repeatable (octreotide in managing carcinoid symptoms refractory to first-generation somatostatin analogues. Adults tumors of the digestive tract were randomly assigned (1:1) receive LAR (60 mg) or (40 every 28 days. Primary outcome was symptom control based on frequency bowel movements and flushing episodes. Objective tumor response secondary outcome....
Treatment options for patients with advanced neuroendocrine tumors are limited. The efficacy of cabozantinib in the treatment previously treated, progressive extrapancreatic or pancreatic is unclear.
Purpose Treatment options for neuroendocrine tumors (NETs) remain limited. This trial assessed the progression-free survival (PFS) of bevacizumab or interferon alfa-2b (IFN-α-2b) added to octreotide among patients with advanced NETs. Patients and Methods Southwest Oncology Group (SWOG) S0518, a phase III study conducted in US cooperative group system, enrolled grades 1 2 NETs progressive disease other poor prognostic features. were randomly assigned treatment LAR 20 mg every 21 days either...
Despite the considerable impact of neuroendocrine tumors (NETs) on patients' daily lives, journey patient with a NET has rarely been documented, published data to date being limited small qualitative studies. NETs are heterogeneous malignancies nonspecific symptomology, leading extensive health care use and diagnostic delays that affect survival. A large, international survey was conducted increase understanding experience identify unmet needs, aim improving disease awareness worldwide.An...
Peptide receptor radionuclide therapy with radiolabeled somatostatin analogs is a novel method of treatment in patients metastatic neuroendocrine tumors (NETs). For the first time United States, we present preliminary results Lutetium (177)(Lu) DOTATATE progressive NETs.Thirty-seven grade 1 and 2 disseminated gastroenteropancreatic NET were enrolled nonrandomized, phase clinical trial. Repeated cycles 200 mCi (7.4 GBq; ±10%) administered up to cumulative dose 800 (29.6 ±10%).Among 32...
Abstract Purpose To assess the impact of baseline liver tumour burden, alkaline phosphatase (ALP) elevation, and target lesion size on treatment outcomes with 177 Lu-Dotatate. Methods In phase 3 NETTER-1 trial, patients advanced, progressive midgut neuroendocrine tumours (NET) were randomised to 177Lu-Dotatate (every 8 weeks, four cycles) plus octreotide long-acting release (LAR) or LAR 60 mg. Primary endpoint was progression-free survival (PFS). Analyses PFS by factors, including ALP size,...
In the phase III RADIANT ‐4 study, everolimus improved median progression‐free survival ( PFS ) by 7.1 months in patients with advanced, progressive, well‐differentiated (grade 1 or grade 2), non‐functional lung gastrointestinal neuroendocrine tumors NET s) vs placebo (hazard ratio, 0.48; 95% confidence interval [ CI ], 0.35‐0.67; P < .00001). This exploratory analysis reports outcomes of subgroup s. ‐4, were randomized (2:1) to 10 mg/d placebo, both best supportive care. is a post hoc ,...
4112 Background: As demonstrated in the primary analysis of phase 3 NETTER-1 trial, 177 Lu-DOTATATE significantly prolonged progression-free survival (PFS) versus high-dose long-acting octreotide, with a HR 0.18 (95% CI: 0.11, 0.29; p < 0.0001), patients advanced, progressive, well-differentiated, somatostatin receptor-positive midgut neuroendocrine tumors (NETs). Here we report final overall (OS) for NETTER-1. Methods: In this international open-label eligible were randomized to receive...
Prospective data are lacking on early somatostatin analog (SSA) therapy in bronchopulmonary neuroendocrine tumors (BP-NETs; typical carcinoids and atypical (TCs ACs)). SPINET (EudraCT: 2015-004992-62; NCT02683941) was a phase III, double-blind study of lanreotide autogel/depot (LAN; 120 mg every 28 days) plus best supportive care (BSC) vs placebo BSC, with an optional open-label treatment (LAN BSC). Patients had metastatic/unresectable, receptor (SSTR)-positive TCs or ACs. Recruitment...
4005 Background: Both VEGF pathway and mTOR inhibitors are active in pNET. Treatment with the inhibitor E improves progression free survival (PFS), but it is not known if addition of a to an enhances antitumor activity This randomized phase II study evaluated or E+B pts advanced Methods: Pts were 1:1 receive either (10 mg po qd) co-administered B mg/kg IV q 2 wks). both arms received concurrent standard dose octreotide. The primary endpoint was PFS. potential superiority vs. assessed using...